Genetic variants in cardiac calcification in Northern Sweden.


Journal

Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R

Informations de publication

Date de publication:
Apr 2019
Historique:
entrez: 16 4 2019
pubmed: 16 4 2019
medline: 23 4 2019
Statut: ppublish

Résumé

Extensive coronary calcification without significant stenosis, described as calcific coronary artery disease (CCAD) may cause abnormal myocardial perfusion and hence generalized ischemia. There is a discrepancy in the expression pattern of CCAD compared to the well-known atherosclerotic disease which raises questions about the exact pathophysiology of coronary calcification and whether there is a genetic etiology for it.In this pilot study we studied 3 candidate genes, ectonucleotide pyrophosphatase/phosphodiesterase (ENPP1), ATP Binding Cassette Subfamily C Member 6 (ABCC6), and 5'-Nucleotidase Ecto (NT5E) involved in pyrophosphate (PPi) and inorganic phosphate (Pi) metabolism, which may predispose to coronary arterial or valvular calcification. We studied 70 patients with calcific cardiac disease; 65 with CCAD (age 43-83 years) and 5 with calcific aortic valve disease (CAVD) (age 76-82 years).Five DNA variants potentially affecting protein function were found in 6 patients. One variant is a known disease-causing mutation in the ABCC6 gene. Our findings support that disturbances in the PPi and Pi metabolism might influence the development of CCAD and CAVD. However, segregation in the families must first be performed to ascertain any damaging effect of these variants we have found.We report 4 new genetic variants potentially related to coronary calcification, through the disturbed Pi and PPi metabolism. The search for direct causative genetic variants in coronary artery and aortic valve calcification must be broadened with other genes particularly those involved with Pi and PPi metabolism.

Identifiants

pubmed: 30985656
doi: 10.1097/MD.0000000000015065
pii: 00005792-201904120-00017
pmc: PMC6485867
doi:

Substances chimiques

ABCC6 protein, human 0
GPI-Linked Proteins 0
Multidrug Resistance-Associated Proteins 0
5'-Nucleotidase EC 3.1.3.5
NT5E protein, human EC 3.1.3.5
Phosphoric Diester Hydrolases EC 3.1.4.-
ectonucleotide pyrophosphatase phosphodiesterase 1 EC 3.1.4.1
Pyrophosphatases EC 3.6.1.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15065

Références

N Engl J Med. 2011 Apr 21;364(16):1577-8; author reply 1579-80
pubmed: 21506753
BMC Med Genet. 2012 Aug 10;13:69
pubmed: 22876777
Invest Ophthalmol Vis Sci. 2003 May;44(5):1824-9
pubmed: 12714611
Circ Res. 2011 Aug 19;109(5):578-92
pubmed: 21852556
Am J Cardiol. 1991 Jul 1;68(1):1-6
pubmed: 2058541
Mayo Clin Proc. 2004 Feb;79(2):197-210
pubmed: 14959915
Int J Cardiol Heart Vasc. 2016 Dec 28;14:41-45
pubmed: 28616562
Eur J Hum Genet. 2017 Nov;25(11):1253-1260
pubmed: 28832569
Carcinogenesis. 2000 May;21(5):887-91
pubmed: 10783308
J Clin Endocrinol Metab. 2007 Jun;92(6):2363-9
pubmed: 17374704
Brief Bioinform. 2013 Mar;14(2):178-92
pubmed: 22517427
Biochemistry. 1998 Nov 17;37(46):16440-4
pubmed: 9819237
Genet Test Mol Biomarkers. 2010 Feb;14(1):75-8
pubmed: 19929409
Int J Cardiol. 2013 Sep 30;168(2):1697-9
pubmed: 23597571
Int J Cardiol. 2013 Aug 10;167(3):1050-2
pubmed: 23176773
Trends Cardiovasc Med. 2012 Aug;22(6):145-9
pubmed: 23122642
Circulation. 2002 Aug 13;106(7):773-5
pubmed: 12176944
Atherosclerosis. 2016 Sep;252:32-39
pubmed: 27494449
Int J Cardiol. 2016 Mar 15;207:13-9
pubmed: 26784565
Ophthalmic Genet. 2014 Dec;35(4):241-7
pubmed: 24918165
J Clin Invest. 1989 Dec;84(6):1762-6
pubmed: 2556444
J Gen Virol. 1998 Jun;79 ( Pt 6):1347-52
pubmed: 9634074
Nat Biotechnol. 2011 Jan;29(1):24-6
pubmed: 21221095
Nucleosides Nucleotides Nucleic Acids. 2016 Dec;35(10-12):726-731
pubmed: 27906615
Arch Biochem Biophys. 2002 May 15;401(2):155-63
pubmed: 12054465
Biochemistry. 1997 Jul 8;36(27):8202-8
pubmed: 9204864

Auteurs

Urban Hellman (U)

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Stellan Mörner (S)

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.

Michael Henein (M)

Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden.
Molecular & Clinical Sciences Research Institute, St. George University, London.
Brunel University, Middlesex, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH